Topic

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

Articles

Biopharma companies responding to the COVID-19 outbreak think accelerating the development of vaccines is safe.

Can Vaccine Development Be Safely Accelerated?

The strategic alliance provides an integrated product offering around drug discovery and development.

PMI Biopharma Solutions, Nashville Biosciences Partner on Comprehensive Drug Discovery

Experts explore the role gene-editing techniques can play in regenerative medicine and cell-line development.

Gene-Editing Techniques Target New Applications

In this collaboration, AbCellera will apply its expertise to generate panels of antibody candidates for Gilead to evaluate.

Gilead, AbCellera in Therapeutic Antibody Discovery Collaboration

Researchers at the University of Sheffield, Sheffield, UK, have discovered and developed a new compound that can kill antibiotic-resistant bacteria, including Escherichia coli.

New Compound Discovered that Kills Antibiotic-Resistant Microbes

The companies will join forces to use artificial intelligence (AI) and machine learning to discover and develop new treatments for two chronic diseases.

AstraZeneca, BenevolentAI Partner on AI for Drug Discovery

Valitacell and Solentim, have announced a collaboration aimed at the acceleration of discovery and development of biologic drugs and advanced cell therapies.

Valitacell, Solentim Collaborate to Accelerate Development of Breakthrough Medicines

Researchers at the University of Delaware have made a step forward in gene therapy by engineering microparticles that deliver gene-regulating material to hematopoietic stem and progenitor cells, which live deep in bone marrow and direct the formation of blood cells.

Gene Therapy Holds Promise for Blood Disorders

A new gene therapy can turn certain brain glial cells into functioning neurons, which could help repair the brain after a stroke or during neurological disorders like Alzheimer’s or Parkinson’s diseases, according to researchers at Penn State.

Brain Glial Cells Reprogrammed into Working Neurons

Researchers at Vanderbilt University Medical Center have isolated the first human monoclonal antibodies (mAbs) that can neutralize norovirus, a virus that causes acute gastrointestinal (GI) illness.

Discovery Pipeline